IL17A and rheumatoid arthritis: IL-17A activates osteoblasts and synovial fibroblasts to express RANKL, which is required for osteoclast differentiation (Kotake et al. 1999; Sato et al. 2006), and thus, IL-17A contributes to bone destruction in RA.